Indigo Ag

Phase A — Understand the business

Lens 1 · Company Overview

What it is today vs. what it was sold as. Indigo Agriculture (founded 2013 as Symbiota by Flagship Pioneering's Noubar Afeyan and Geoffrey von Maltzahn; rebranded Indigo in Feb 2016 ) was, at its 2021–22 peak, one of the most richly funded agtech startups in the world — pitched as a company that would "rewire" agriculture through the plant microbiome and a set of digital/financial marketplaces, and described in the press as potentially "more disruptive than Netflix or Airbnb". As of mid-2026 it is a far smaller business that has retreated to two core lines:

1. Sustainability Solutions (Carbon by Indigo) — the load-bearing leg. Indigo originates, measures (MRV), and brokers agricultural soil-carbon removal credits, taking a cut and passing ~75% of credit value to the enrolling farmer. It markets itself as the largest registry-issued ag soil-carbon program globally.
2. Biological Products (biotrinsic®) — microbial seed treatments and biofungicides/bionematicides that descend from the original microbiome thesis. Newest product: biotrinsic® Nemora FP™, a bionematicide for soybean cyst nematode, available Spring 2026.

What it abandoned. The two businesses that justified the unicorn valuation — Indigo Marketplace (an online grain-trading marketplace meant to disintermediate Cargill/ADM, which had >$6B of grain listed at peak ) and Indigo Transport (an "Uber for grain trucking" using idled trucks ) — have been wound down or de-emphasized as "non-core." Bloomberg's framing in June 2024 was blunt: "Farm Startups Like Indigo Ag Bent on Shaking Up Cargill, ADM Are Floundering".

Customers / counterparties. On the carbon side the customers are corporate Scope-3/net-zero buyers — anchored by Microsoft (three transactions: 40,000 t in 2024, 60,000 t in 2025, and a landmark 2.85M-tonne, 12-year agreement announced late 2025/2026 ), plus historically Anheuser-Busch, Dogfish Head, Corteva, North Face/VF Corp on supply-chain/MRV programs. The suppliers are the ~8 million acres of US farmers Indigo enrolls; the competitors are other ag-carbon programs (Lens 3) and incumbent input/biological majors. Contract structure on carbon is outcome-based (pay-on-verified-credit), not take-or-pay; on biologicals it is conventional product sales through ag-retail channels. customers.csv is empty — all of the above is ``.

Bottom line for Lens 1: the business you would actually be buying today is a soil-carbon MRV-and-brokerage shop with a small biologicals product line bolted on — not the "biology platform" or the "grain-marketplace disruptor" the 2021 valuation paid for.

Lens 2 · Supply Chain

Indigo sits in the middle of two distinct value chains. Naming the actual links:

Carbon credit chain (the core): US row-crop farmers (≈8M enrolled acres, corn/soy/wheat) → [practice change: cover crops, reduced/no-till, N management] → Indigo (enrollment, agronomy, MRV: soil sampling + remote sensing + biogeochemical modeling) → registry/verifier (Climate Action Reserve — Soil Enrichment Protocol; also referenced Verra-style standards) → issued credits → corporate buyers (Microsoft anchor; also other net-zero corporates) → retirement against Scope-3.

• Chokepoint / single-source dependency #1: the registry + protocol. Indigo does not set the rules — the Climate Action Reserve (and the broader integrity bodies) gate whether a credit is issuable and saleable. A protocol tightening on additionality/permanence (a live risk, Lens 10/13) directly throttles supply.
• Chokepoint #2: buyer concentration. Microsoft is the whale. A 2.85M-tonne, multi-year offtake from one hyperscaler is both the company's biggest asset and its biggest single-counterparty dependency.
• Chokepoint #3: the farmer's reversibility. The "input" (sequestered carbon) can walk back out of the soil if the farmer reverts to tillage or hits drought — the supply is physically non-permanent (Lens 10).

Biologicals chain: Microbial strain discovery (legacy Indigo microbiome library) → fermentation/formulation (CDMO/contract manufacturing — not disclosed) → seed-treatment / in-furrow product (biotrinsic line) → ag-retail distribution → farmer. This chain is conventional crop-input economics; Indigo is a small player against the biologicals arms of Corteva, Bayer, Syngenta, BASF, Novonesis (Lens 3).

supply-chain.md is missing on the shelf; the above is reconstructed ``. The honest read: Indigo's "supply chain" is mostly a measurement-and-trust pipeline, not a physical one — its product is verified tonnes, and the fragile links are the registry, the buyer, and the permanence of dirt.

Lens 3 · Competitive Advantages (moats)

Claimed moats:

• Scale of enrolled acreage + data (≈8M acres, largest registry-issued ag soil-carbon program ) — a real first-mover/aggregation lead in US row-crop carbon.
• MRV credibility — Indigo positions its quantification (soil sampling + remote sensing + modeling on a Climate Action Reserve protocol) as "industry-leading for transparency and data quality" per third-party reviewers it cites. In a market where ~95% of projects fail integrity screens, being one of the credible ones is the moat.
• The Microsoft relationship — a repeat, scaling, name-brand offtake is a powerful demand-side proof point and a sales reference.

How durable is any of it? Skeptically:

• Switching costs are low for buyers. A corporate carbon buyer can purchase soil-carbon credits from Agreena, Agoro, Boomitra, Truterra, Nori, or directly from a registry. Indigo's credits compete on price and integrity, not lock-in.
• The "data moat" is contested. Soil-carbon quantification is increasingly a commodity methodology problem — academic work (Dupla 2024, Soil Use & Management; CarbonPlan 2024) argues current MRV is systematically shaky across all 10 public protocols, which both undercuts the integrity premium and commoditizes the technical edge.
• Bargaining power is weak on both sides. Indigo needs the farmers (who can enroll elsewhere) and needs the buyers (concentrated in a few corporates) more than they need Indigo. The 75% farmer share is itself evidence of weak supplier-side pricing power — Indigo keeps a thin slice.
• Biologicals moat is shallow vs. Corteva/Bayer/Syngenta/Novonesis, who have distribution, registration scale, and balance sheets Indigo can't match.

Verdict (Lens 3): Indigo's only defensible asset is a brand-and-scale lead in credible US ag soil-carbon — an aggregation/reputation moat, not a structural one. It is real but narrow, and it is being eroded from above (protocol integrity scrutiny) and beside (well-capitalized ag-carbon rivals). Ground files positioning.md/bottlenecks.md are missing; assessment is +.

Lens 4 · Segments

segments.csv is empty — Indigo discloses no audited segment P&L (private). What is known qualitatively ``:

Revenue magnitude (unaudited, conflicting): management guided in 2023 to revenue "up to $100M in 2024" after the $250M/$270M raise. Note this is a fraction of the >$6B grain GMV that used to flow through Marketplace — GMV ≠ revenue, and the collapse of the marketplace ambition means even the top-line story shrank by an order of magnitude. There is no `` segment number to cite — n/a — private, not disclosed for any precise split.

Trend read: the segment mix has deliberately narrowed — from a four-pillar "rewire-ag" sprawl to a two-pillar carbon-+-biologicals focus under Dean Banks (2024 restructuring). That is rational triage, but it means the company decelerated by amputation, not by losing to competition in those lines.

---

Phase B — Measure performance

Lens 5 · "Earnings Result" → Funding & Valuation Trajectory (+private lens-swap)

No earnings. The scoreboard for a private is the round history and valuation path, and Indigo's is one of the starkest down-rounds in agtech:

• Cumulative raised: ~$1.4B over ~10 rounds / 28 investors — one source says $1.98B; the discrepancy is unreconciled and I flag it rather than pick one. David Perry stated >$1.2B in equity raised during his tenure alone, consistent with the ~$1.4B cumulative.
• The headline number: valuation fell from ≈$4B (Jul 2022) to ≈$200M (2023) per PitchBook/press — ~94–95% destruction. Even taking the company's protest that "$200M" is wrong, no one disputes a severe, multi-billion markdown.
• Down-round investor pain: at least one investor (Israel-based partnership) was reported carrying a loss on its Indigo position into the recap. Crossover/IPO-tell funds (Fidelity/T.Rowe/Coatue) are absent from the recent cap table — the new money is a pension fund (Michigan SERS) and a European holding-co vehicle (Lingotto/Exor), i.e. value/strategic capital, not IPO-proximity capital.

Read: the "print" here is a >90% equity wipeout and a business that had to be rescued by insiders. Any new investor enters below a long line of impaired preferred stock — the liquidation-preference overhang alone makes the common/seed economics brutal (Lens 11).

Lens 6 · "Earnings Calls" → Founder/CEO commentary trend (+private lens-swap)

No earnings calls. The sentiment proxy is CEO messaging across the three regimes, and the arc is telling:

• David Perry era (2015–Sep 2020): maximalist. The pitch was civilization-scale — microbiome → yield → "feed the planet sustainably," marketplaces to disrupt the grain majors. Tone: visionary, TAM-the-world.
• Ron Hovsepian era (Sep 2020–Jan 2024): the retrenchment voice. Hovsepian (an enterprise-software turnaround operator, ex-Novell) reframed around "four core offerings" and ran the first layoff rounds — language shifted from "disrupt" to "streamline" and "path to profitability".
• Dean Banks era (Feb 2024–present): the discipline-and-focus voice. Ex-Tyson CEO, now also a Flagship CEO-Partner. His framing is explicitly humble: "it's easier to talk about disrupting than it is to actually disrupt". He split the company into two units (Biologicals under Georg Goeres, Sustainability under Ewan Lamont), appointed a new CTO (Bernie Barbour), and ran a third round of layoffs, pursuing "a decisively lower cost structure".

The "things they stopped saying": "rewire agriculture," "more disruptive than Netflix," grain-marketplace TAM. The recurring phrases now: "path to profitability," "core," "de-risk," "high-integrity credits." That linguistic migration is the company's story — from a venture moonshot to a survival-mode operating business. transcripts/ empty; all ``.

Lens 7 · "Comps" → Ag-carbon & biologicals peer set (+private lens-swap: by market position, not P/E)

No public multiple exists for Indigo (private, no disclosed financials) — n/a for EV/Sales, EV/EBIT, P/E, yield, ROE. The honest comp is competitive position in the two markets, with what's ``-sourceable:

Agricultural soil-carbon (the core market):

Top-5 (Indigo, Agreena, Agoro, Boomitra, GreenCollar) held >35% of the 2024 voluntary ag-carbon market. The total addressable market is tiny: voluntary ag-carbon was ~$36.1M in 2024 (GMInsights) — note the order-of-magnitude conflict with a separate "soil carbon market $1.52B in 2025" figure; the gap is almost certainly voluntary ag-soil-carbon credits ($36M) vs. all soil-carbon incl. broader CDR / projected ($1.5B) — I surface the conflict; do not merge. Even the generous figure projects only to ~$5.8B by 2034 at ~16% CAGR.

Biologicals (the second leg): competes against the biologicals arms of Corteva, Bayer, Syngenta, BASF, Novonesis (Chr. Hansen/Novozymes), Pivot Bio, Sound Agriculture — all of which dwarf Indigo in distribution and registration capital. No clean public-comp multiple for the segment; n/a.

Comp verdict: Indigo is a share leader in a structurally small, integrity-challenged voluntary market, and a sub-scale also-ran in biologicals. There is no public valuation anchor; the last private mark (~$200M, disputed) is the only number, and it is stale and contested.

Lens 8 · "Stock-Price Catalysts" → Valuation/funding catalysts (+private lens-swap)

No stock. The events that moved Indigo's private valuation / narrative (the equivalent of the >5% moves):

• 2017–2020 — the run-up: serial mega-rounds ($156M→$250M→~$500M), unicorn (2017), Moderna CEO Stéphane Bancel joining the board (2020), FedEx/Alaska Permanent backing → narrative peak, $3.5B.
• Jul 2022 — the top: ≈$4B PitchBook mark, last high-water.
• 2022–2023 — the agtech bust: rate shock + the broad collapse of "disrupt-the-grain-majors" agtech (peers Farmers Edge taken private at a fraction of IPO; Gro Intelligence shut down ). Indigo's marketplace/transport theses died here.
• Sep 2020 / Jan 2024 — CEO changes: Perry→Hovsepian, then Hovsepian→Banks — each a regime/strategy reset.
• Aug–Sep 2023 — the recap: the ~$250–270M raise at the ~$200M-reported valuation; the down-round itself was the defining "catalyst".
• 2024–2026 — the Microsoft escalation: 40k → 60k → 2.85M-tonne offtake — the single most positive demand signal of the recent period, and the spine of any bull case.

Pattern the "market" reacts to for Indigo: in the boom, narrative and round size; in the bust, the absence of a profitable, durable business model. The carbon-offtake wins move sentiment now, but no funding event since 2023 has re-rated the valuation upward in any sourced figure (the Jan-2026 "$50M" round carries no disclosed valuation). All ``.

---

Phase C — Judge people & books

Lens 9 · Management

• Founders / sponsor: Flagship Pioneering (Noubar Afeyan) conceived the company in its VentureLabs foundry; Geoffrey von Maltzahn is the scientific co-founder. Flagship has been the through-line investor and led the 2023 rescue — Indigo is a Flagship portfolio company to its core, and the CEO seat now doubles as a "Flagship CEO-Partner" role. Implication: governance and capital are sponsor-dominated; minority/common investors ride alongside a controlling venture house with its own portfolio incentives.
• Founding CEO — David Perry (2015–2020): genuinely strong pedigree. Co-founded Anacor Pharmaceuticals → acquired by Pfizer for ~$5.2B (2016); raised >$1.2B for Indigo. This pedigree is exactly why the early valuation ran so hot — investors paid a "proven serial founder" premium. Perry left in Sep 2020 (well before the markdown) and moved on to Better Therapeutics (chair) and Evelo Biosciences (board) — note Better Therapeutics itself later failed/wound down, a mark against the "Midas touch" read. Capital-allocation verdict on his Indigo watch: built the moonshot, also built the cost base and the over-broad four-pillar sprawl that had to be dismantled.
• Turnaround CEO — Ron Hovsepian (2020–2024): enterprise-software operator (ex-Novell/Intralinks). Brought in to commercialize/cut; ran the first layoffs and the "four core offerings" refocus. Oversaw the period in which the valuation collapsed — though much of that was macro/sector, not idiosyncratic.
• Current CEO — Dean Banks (Feb 2024–): ex-Tyson Foods CEO, ex-SpaceX/Google[X] background, Flagship CEO-Partner. The most operationally credible profile for this phase (food/ag + hard-tech + discipline). His 2024 reorg (two units, new CTO, third layoff round) is textbook focus-and-survive. Skin in the game: as a Flagship-installed CEO-Partner, his alignment is with the sponsor's portfolio outcome more than founder-equity; insider-ownership specifics n/a — private, not disclosed.
• Board signal: Stéphane Bancel (Moderna) joined in 2020; the recent cap table added a pension fund (Michigan SERS) and Exor's Lingotto — operator/strategic capital, not growth/IPO capital.

Red flags (management): three CEOs in ~4 years; three rounds of layoffs; a strategy that was publicly maximalist then publicly amputated; a controlling sponsor whose CEO-Partner construct blurs the line between company and fund. Founder-vs-professional archetype: founder-built, now professionally-managed in salvage mode — the right archetype for survival, the wrong one for a re-acceleration story. insider-transactions.csv absent; all ``.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst with no financials to forensically examine — which is itself the first red flag:

1. Opacity is the headline risk. No audited statements, no segment P&L, no disclosed margins, and the company refused to comment on its own valuation ("no comment" to AgFunder, 2023). For a would-be investor, you cannot verify revenue quality, gross margin, burn, or runway from any primary source. n/a — not disclosed is the answer to almost every forensic question.
2. GMV-vs-revenue conflation risk. The company's most-cited "scale" metrics are non-financial (acres enrolled, tonnes verified, ">$6B grain listed," "$40M paid to farmers"). None of these is revenue. The >$6B grain figure in particular is gross merchandise value of a now-wound-down business — a classic vanity-metric trap. Treat any tonnage/acreage headline as marketing, not accounting.
3. Carbon-credit revenue recognition is inherently soft. Outcome-based, multi-year offtakes (e.g., Microsoft 2.85M t over 12 years) raise the question of when and how revenue is booked vs. credits delivered — impossible to audit externally. If/when Indigo ever files (S-1), this is the line item to scrutinize first.
4. Asset-quality / permanence risk on the core product. The product is sequestered soil carbon, which physically reverses (15–25% reversal within 10 years of practice cessation; reversal possible in 3–5 years on tillage return ). A credit inventory whose underlying asset can leak is a contingent-liability question buyers and registries are increasingly pressing.
5. Going-concern lineage. A 94%-ish markdown plus an insider-led rescue plus repeated layoffs is a textbook distressed-capitalization pattern. Whether the Jan-2026 "$50M" tops up runway or signals continued cash strain is n/a — undisclosed.

Regulatory findings (required sub-section).

• SEC (EDGAR LR + AAER): 0 findings. Indigo has no CIK — it is private and not an SEC filer, so no EDGAR enforcement search is possible..
• Non-SEC (web search "Indigo Ag" (FTC OR DOJ OR FDA OR CFPB OR consent decree OR settlement OR fine OR penalty)): no material enforcement actions, consent decrees, or fines surfaced against Indigo Agriculture as of 2026-06-20. The relevant regulatory exposure is indirect and market-structural, not company-specific: the voluntary-carbon-market integrity backlash (e.g., the 2024 Berkeley finding that cookstove credits were ~10× over-credited, and CarbonPlan/academic critiques of soil-MRV protocols) is a demand and reputational risk to the whole asset class, which spilled over to dampen soil-carbon demand in 2024. Registry/protocol tightening (Climate Action Reserve, ICVCM Core Carbon Principles) is the regulatory-adjacent force most likely to affect Indigo.
• Item 3 (Legal Proceedings): n/a — no 10-K exists (private, no EDGAR).
• Summary: No material company-specific regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER: 0) and web search as of 2026-06-20; the live regulatory risk is category-level carbon-market integrity, not an action against Indigo.

---

Phase D — Project & stress-test

Lens 11 · "Forward Projection" → IPO-readiness & path-to-tradeable (+private lens-swap)

No EPS to project (private, no revenue disclosure). The +private job is to assess time-to-tradeable and what a realistic exit looks like. Indigo is not in research/private-watch.json, so there is no pre-scored readiness row — I assign one from web evidence against the file's scale (1=seed … 4=pre-IPO/secondary-active … 5=S-1 filed/imminent):

• Assigned IPO-readiness: ~2 / 5 (growth/recovery stage, de-rated from its former pre-IPO status).
• Why not higher: the IPO that was once "prepared for" is explicitly off the table; the cap table is being rescued by value/strategic money, not crossover funds (no Fidelity/T.Rowe/Coatue mark-up — the classic IPO-proximity tell is absent); three layoff rounds and a focus-to-survive posture signal consolidation, not pre-listing scaling.
• Why not lower: it is still operating, still raising (Jan-2026 $50M, if real), still landing marquee offtakes (Microsoft 2.85M t), and has a recognizable brand — it is a recovery story, not a zombie.
• Catalysts that would unlock a tradeable event: (1) a sustained, disclosed path to profitability in the carbon + biologicals core; (2) the voluntary-carbon market re-rating upward on restored integrity (ICVCM CCP labels, CAR protocol credibility) so credit pricing/volume inflects; (3) a strategic acquirer — a fertilizer/seed/input major or a co-op (Yara/Agoro logic, Corteva, Bayer, Land O'Lakes/Truterra) buying the carbon-origination scale and farmer relationships is the far more plausible exit than an IPO.
• The economics overhang (the number that actually matters for a buyer): after a ~94% markdown and ~$1.4B of cumulative preferred raised, the liquidation-preference stack almost certainly exceeds the current enterprise value — meaning new common/seed economics are deeply impaired and even a "recovery" likely pays back preferred before common sees much.. This is the single most important quantitative point in the dossier, and it is `` because the actual stack is undisclosed.

Forecast log: Skipped — per --watchlist rules, do not forecast.ts create in the breadth loop, and there is no clean binary/EPS line to score for a private with undisclosed financials. The natural future forecast to log (in a later, deliberate pass) would be a binary on a tradeable/strategic-exit event by a date (e.g., "Indigo announces an S-1 or a strategic acquisition by YE2028" — base p low).

Lens 12 · Bull vs Bear

Bull case. Indigo is the scaled, credible incumbent in US agricultural soil-carbon at the exact moment corporate Scope-3 demand is structurally rising and the market is climbing out of its "trough of disillusionment". The Microsoft relationship — escalating from 40k to 60k to 2.85M tonnes over 12 years — is a multi-year, name-brand demand annuity that validates both the MRV and the offtake model, and it's the kind of anchor that pulls other corporates in. The biologicals line (biotrinsic) gives a second, product-revenue leg with real agronomic value (nematode/disease pressure is a genuine farmer pain point) descending from a deep microbiome IP estate. Under Dean Banks the cost base is finally rational, the strategy is finally focused, and the entry valuation (~$200M, post-94%-markdown) means the moonshot premium is fully gone — anyone buying now buys the operating business, not the hype. If ag-carbon pricing/volume inflects and Banks delivers a profitable core, a strategic acquirer (input major / co-op) could pay a meaningful multiple of today's distressed mark for the #1 farmer-carbon franchise.

Bear case. Three things could permanently impair this business: (1) the core asset's integrity is structurally suspect — soil carbon is non-permanent and the MRV is academically contested (Dupla 2024, CarbonPlan), so the whole credit category sits one scandal away from a demand collapse, and Indigo's "we're the credible one" defense is only as good as the next protocol audit. (2) The market is just small and thin — voluntary ag-carbon was ~$36M in 2024; even the most generous "soil carbon" framing is ~$1.5B and projected to only $5.8B by 2034. A share leader in a small market is a small company, and Indigo keeps only a thin slice (75% goes to the farmer). (3) It already failed once at its biggest ambitions — grain marketplace and transport, the parts that justified the $3.5–4B, are dead; what's left was always the smaller part of the story. Layer on the liquidation-preference overhang ($1.4B prefs vs ~$200M EV — common is likely under water), three CEOs in four years, and three layoff rounds, and the expectations baked into even the reduced private mark may still be too high.

Pre-mortem (18 months out, thesis broke — what happened?): A voluntary-carbon-market integrity scandal (a high-profile soil-carbon over-crediting finding, or an ICVCM/registry tightening that invalidates a chunk of issued credits) craters buyer demand; Microsoft slows or restructures the offtake; the Jan-2026 raise turns out to have been a bridge, not a base, and Indigo runs short of runway into a frozen ag-carbon market — forcing either a fire-sale to a strategic at a price that wipes out everything below the senior preferred, or a quiet wind-down of the carbon unit back to a pure (sub-scale) biologicals business.

Are the multiples too high? There is no public multiple. But the last private mark (~$200M) still embeds a recovery/optionality premium over a pure-biologicals-business valuation, and given the preference stack, common-equity value is plausibly near zero until a profitable, disclosed core is proven.

Contrarian view (what the market refuses to see): The consensus frames Indigo as a fallen unicorn slowly recovering. The contrarian read is that Indigo is no longer a venture-return asset at all — it is a strategic/industrial asset mispriced as a recovering startup. Its real value is the farmer relationships + carbon-origination plumbing + MRV credibility, which are worth far more inside a Yara/Corteva/Bayer/co-op than as a standalone "agtech" with a dead IPO path and an impaired cap table. The upside, if any, is an acquisition, not an inflection — and that upside accrues to senior preferred, not to a new common-equity buyer.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• The product can literally evaporate. I am being asked to value a company whose flagship inventory — sequestered soil carbon — leaks back into the atmosphere if a farmer tills or a drought hits (3–5 yr reversal risk; 15–25% over 10 yr ). No other "commodity" you underwrite physically un-creates itself. The registries know this, which is why protocols keep tightening — and every tightening is a supply cut for Indigo.
• Revenue is concentrated and undisclosed — a double sin. The demand story rests heavily on one buyer (Microsoft). If that single relationship slows, restructures, or simply doesn't renew at scale, the carbon top line is exposed. And I can't even size the risk because there are no financials — the company won't disclose revenue and refused to comment on its own valuation. Opacity + concentration is exactly the profile shorts love.
• The moat is a reputation, and reputations in this market are fragile. Indigo's "integrity" edge is a marketing claim policed by third parties; a single CarbonPlan-style teardown or a registry de-listing of issued credits would convert the moat into a liability overnight. ~95% of carbon projects fail integrity screens — the base rate is against the category.
• The most dangerous competitor bulls underestimate: not Boomitra or Nori — it's the strategics with balance sheets and distribution (Yara/Agoro, Corteva, Bayer, Land O'Lakes/Truterra). They can bundle carbon with inputs they already sell, undercut Indigo's economics, and out-wait it. Indigo has no balance sheet to win a price war.
• Capital-allocation / governance: three CEOs in four years, three layoff rounds, a maximalist strategy publicly dismantled, and a controlling sponsor (Flagship) whose installed "CEO-Partner" sits across the company and the fund — minority economics are subordinate to both a deep preference stack and a sponsor's portfolio agenda.
• What must hold for even the ~$200M mark: that ag-carbon pricing and volume inflect, that integrity scrutiny doesn't crater demand, that Microsoft scales as signaled, and that the cost cuts reach profitability before the cash runs out. If growth/credit-pricing disappoints by 20–30%, a thin-margin broker in a ~$36M–$1.5B market with a $1.4B preference overhang is worth, to a new common buyer, plausibly ~zero — the value, if any, transfers to senior preferred in a strategic sale.
• The single scenario that permanently impairs it: a voluntary-carbon-market integrity collapse (the "cookstove moment" for soil carbon) that simultaneously (a) destroys buyer demand and (b) invalidates a tranche of issued credits — turning the carbon unit from the company's one good leg into a stranded asset, and leaving only a sub-scale biologicals also-ran. Plausibility: moderate-and-rising, given the academic and market-integrity trajectory.

Lens 14 · Management Questions (ordered by information value)

1. Show the actual P&L: what was 2025 revenue, gross margin, and operating cash burn — by segment (carbon vs. biologicals) — and what is current cash runway at the present burn?
2. What is the full liquidation-preference stack today, and what does the common/ordinary equity see in a $300M / $600M / $1B strategic-sale scenario?
3. How is carbon revenue recognized under multi-year offtakes like Microsoft's 2.85M-tonne/12-year deal — at contract, at issuance, or at delivery — and how much of that contract is recognized to date?
4. What percentage of total revenue is Microsoft, and what is the buyer concentration of the top 3 carbon customers?
5. If a registry or ICVCM action invalidated or downgraded a tranche of already-issued credits, what is Indigo's financial and contractual exposure (buybacks, indemnities, reversal buffers)?
6. What is the gross margin on a carbon credit after MRV (soil sampling + remote sensing + modeling), aggregation, and the 75% farmer share — i.e., what does Indigo actually keep per tonne?
7. Is the IPO genuinely off the table, and if so, is the base-case exit a strategic sale — and to which category of acquirer (input major, co-op, carbon platform)?
8. What was the fully-diluted post-money valuation of the Jan-2026 "$50M" round, who led it, and was it primary growth capital or a bridge?
9. On permanence/reversal: what reversal-buffer pool does Indigo hold, and how are reversals on enrolled acres detected, accounted for, and made good to buyers?
10. What is the unit economics and attach rate of the biotrinsic biologicals line, and can it stand alone if the carbon unit stalls?
11. Why should this team win against strategics (Yara/Agoro, Corteva, Bayer, Truterra) who can bundle carbon with inputs and out-spend Indigo on distribution?
12. What is the farmer retention/re-enrollment rate year-over-year on carbon acres, and what is the churn driver?
13. Given three CEOs in four years and three layoff rounds, what specifically is different now that makes the current strategy durable rather than the fourth pivot?
14. How does the Flagship "CEO-Partner" governance construct resolve conflicts between Indigo's standalone interests and Flagship's broader portfolio?
15. What is the 3-year capital plan — does Indigo reach self-funding profitability on the current cash, or is at least one more raise required, and at what implied valuation?

---